Eyeing Duchenne MD cure, The Column Group gambles $40M on CRISPR/Cas9 startup Exonics – Endpoints News
Endpoints News |
Eyeing Duchenne MD cure, The Column Group gambles $40M on CRISPR/Cas9 startup Exonics
Endpoints News The Column Group thinks that gene editing may provide just the right kind of technology needed to cure Duchenne muscular dystrophy. And the investment group is wagering $40 million that the preclinical mouse data used to back biotech startup Exonics is … Exonics Therapeutics Raises $40 Million in Series A Financing Funds to support continued development of SingleCut … |
